CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Phase 1 data shows sabirnetug (ACU193) is safe, reduces amyloid plaques, and supports ongoing Phase 2 trial for early Alzheimer’s disease. The press release implies that while there were positive ...

Spyrosoft Group, a leading consulting and software development company, is proud to announce the launch of Spyrosoft Ad tech, a new entity focused on building custom advertising and marketing software ...

Over the past few decades, neuroscientists and medical researchers worldwide have been trying to leverage available health ...

The last time I spoke about Nektar Therapeutics (NKTR) it was with a Seeking Alpha article entitled "Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC." With respect to ...